Uses
(S)-SLV 319 is a potent, selective CB1 receptor antagonist.
Biological Activity
ki: 7.8 and 7,9 nm for cb1 and peripheral cannabinoid (cb2), respectively(s)-slv 319 is a cb1 receptor antagonist.it has been reported that central cannabinoid (cb1) receptor antagonists may have potential in the treatment of a variety of diseases including cognitive disorders, neuro-inflammatory disorders, obesity, septic shock, psychosis, addiction, as well as gastrointestinal disorders.
in vitro
previous study found that (s)-slv 319 was a potent and selective cb1 receptor antagonist with ki values of 7.8 and 7,9 nm for cb1 and cb2, respectively. in addition, (s)-slv 319 was found to be less lipophilic and thus more water soluble than other previously identified ligands of cb1 receptor [1].
in vivo
previous animal study showed that in rats exposed to an ambient temperature of 22°c, a moderate dose of lps at 25 - 100 μg/kg could induce a fall in body temperature. such response was not affected by desensitization of intra-abdominal trpv1 receptors with resiniferatoxin at 20 μg/kg, by systemic trpv1 antagonism with capsazepine at 40 mg/kg, or by systemic cb2 receptor antagonism with sr144528 at 1.4 mg/kg. in contrast, cb1 receptor antagonism by slv319 at 15 mg/kg or rimonabant at 4.6 mg/kg was able to block lps caused hypothermia [2].
References
[1] j. h. m. lange, h. h. van stuivenberg, w. veerman, et al. novel 3,4-diarylpyrazolines as potent cannabinoid cb1 receptor antagonists with lower lipophilicity. bioorganic & medicinal chemistry letters 15, 4794-4798 (2005).
[2] steiner aa et al. the hypothermic response to bacterial lipopolysaccharide critically depends on brain cb1, but not cb2 or trpv1, receptors. j physiol. 2011 may 1;589(pt 9):2415-31.
